New hope for rare cancers: drug targets genetic weakness

NCT ID NCT06390839

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This phase II trial tests the drug palbociclib in 43 patients with advanced cancers that have extra copies of the CDK4 or CDK6 genes. The drug works by blocking signals that tell cancer cells to multiply. Researchers will measure how many patients' tumors shrink or stop growing for at least 6 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: palbociclib (a kinase inhibitor pill that blocks cancer cell growth signals)
What this could lead to: If successful, this could provide a targeted treatment option for patients with certain hard-to-treat cancers that have CDK4 or CDK6 gene changes.
What could go wrong: This is a small, early-phase trial (43 patients) with no control group, so results may not apply broadly. Palbociclib can cause side effects like low blood counts and fatigue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer lymphoma refractory hematologic cancer refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED LYMPHOMA ADVANCED MALIGNANT SOLID NEOPLASM REFRACTORY LYMPHOMA REFRACTORY MALIGNANT SOLID NEOPLASM

Contacts and locations

Locations

ECOG-ACRIN Cancer Research Group

Philadelphia, Pennsylvania, 19103, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.